Objective-Lipoprotein lipase (LPL) is a principal enzyme in lipoprotein metabolism, tissue lipid utilization, and energy metabolism. LPL is synthesized by parenchymal cells in adipose, heart, and muscle tissues followed by secretion to extracellular sites, where lipolyic function is exerted. The catalytic activity of LPL is attained during posttranslational maturation, which involves glycosylation, folding, and subunit assembly within the endoplasmic reticulum. A lipasechaperone, lipase maturation factor 1 (Lmf1), has recently emerged as a critical factor in this process. Previous studies demonstrated that loss-of-function mutations of Lmf1 result in diminished lipase activity and severe hypertriglyceridemia in mice and human subjects. The objective of this study is to investigate whether, beyond its role as a required factor in lipase maturation, variation in Lmf1 expression is sufficient to modulate LPL activity in vivo. Methods and Results-To assess the effects of Lmf1 overexpression in adipose and muscle tissues, we generated aP2-Lmf1
L ipoprotein lipase (LPL) is a principal enzyme in plasma lipid metabolism. 1 Through the hydrolysis of triglycerides (TG) associated with lipoprotein particles such as chylomicrons and very low-density lipoproteins, LPL releases fatty acids for utilization and storage in various tissues. LPL is the rate-limiting enzyme in tissue absorption of dietary and endogenously produced TG, hence its activity is a key determinant of tissue lipid partitioning as well as plasma TG levels. Indeed, LPL-deficiency results in elevated plasma TG, 2 whereas LPL-transgenic mice exhibit increased tissue lipid content and insulin resistance. 3 Consistent with mouse models, genetic variation in the LPL gene is associated with insulin resistance, 4 plasma TG concentration, and coronary artery disease 5 in human populations. Thus, tissue LPL activity is a critical determinant of metabolic traits in health and disease.
LPL is synthesized in the endoplasmic reticulum (ER) of parenchymal cells in muscle and adipose tissue followed by secretion and transport to the vascular endothelium, the functional site of LPL action. LPL attains catalytic activity within the ER in a multistep process, herein referred to as lipase maturation, which involves glycosylation, glycan processing, folding, and the assembly of homodimers. 6 In adipocytes, only about 70% to 80% of newly synthesized LPL is converted into active enzyme, whereas the rest remains permanently inactive and undergoes degradation. [7] [8] [9] Thus, posttranslational maturation represents a bottleneck in the generation of active LPL in adipocytes. 10 Several factors have been implicated in lipase maturation including components of the calnexin/calreticulin and BiP/ Grp94 chaperone systems. 11 In addition to general chaperones, which are involved in the posttranslational processing of most proteins traveling through the ER, a lipase-specific chaperone, lipase maturation factor 1 (Lmf1), has also been described. hypertriglyceridemia owing to a lack of LPL activity. Although LPL protein is normally expressed in cld mutant mice, it fails to attain the catalytically active homodimer conformation and is subject to retention in the ER and degradation. 13 Lmf1 is a polytopic protein of the ER membrane and it physically interacts with LPL through a soluble region exposed to the ER lumen.
14 Interestingly, LPL is not the only lipase affected by Lmf1, as hepatic lipase and endothelial lipase activities are also diminished in Lmf1 deficiency in both mouse and human subjects. 12, 15, 16 Similar to LPL, hepatic lipase and endothelial lipase also require homodimerization for catalytic activity. 17, 18 In contrast, the enzymatic activity of pancreatic lipase, a related enzyme that is functional as a monomer, 19 is not dependent on Lmf1 function. 20 Based on these observations, Lmf1 has been proposed to play a role in the assembly of folded lipase subunits into active dimers, or stabilization of the latter. 21 To date, the identity of factors limiting the efficiency of LPL maturation in vivo has remained unknown. Based on in vitro studies implicating dimerization as a major bottleneck in lipase maturation 22 and the suspected role of Lmf1 in this process, we hypothesized that Lmf1 may be a rate-limiting factor in the generation of active LPL. 23 To test this hypothesis, we overexpressed Lmf1 in adipose, heart, and muscle tissues of transgenic mice. Our results demonstrate that elevated cellular levels of Lmf1 result in increased LPL activity in all tissues tested. Although Lmf1 overexpression increased LPL specific activity, but not LPL mass, in omental and subcutaneous adipose tissues, the converse (ie, higher LPL mass, but no change in specific activity) was observed in heart and the gonadal adipose depot. We also extended these studies to humans by investigating the relationship between LMF1 and LPL using association analysis and detected significant association between genetic variants in LMF1 and postheparin LPL activity. Taken together, our results indicate that Lmf1 is not only required for lipase maturation, but experimental and natural variation in LMF1 expression can also modulate LPL activity in vivo.
Methods
A detailed description of methods is provided in in the online-only Data Supplement. aP2-Lmf1 and Mck-Lmf1 transgenic mice have been generated on the FVB/J genetic background, maintained in a specific pathogen-free facility under 14:10 hour light cycle, and were fed a chow diet. All animal studies were approved by the Institutional Animal Care and Use Committee at the Cedars-Sinai Medical Center. Human study participants were recruited in the Helsinki and Turku University Central Hospitals and gave informed consent. The study design was approved by the ethics committees of the participating centers.
results elevated LPL activity in aP2-Lmf1 transgenic Mice
To investigate the role of Lmf1 in adipose tissue, we generated transgenic mice with elevated Lmf1 expression using the 5.4-kb enhancer/promoter region of the aP2 gene ( Figure 1A ), which directs expression in terminally differentiated adipocytes. 24, 25 To facilitate the detection of exogenous Lmf1 protein in tissues, we included an N-terminal myc epitope tag, which does not interfere with the lipase maturation function of Lmf1. 26 As determined by immunoblotting with an anti-myc antibody, the transgene-derived myc-Lmf1 protein was specifically expressed in subcutaneous, omental and, at a lower level, gonadal adipose tissue in aP2-Lmf1 mice ( Figure 1B and 1C) . To assess the relative expression of endogenous versus exogenous Lmf1, we performed immunoblotting with an antibody recognizing the C-terminus of the protein. 12 Myc-Lmf1 expression in gonadal adipose was comparable (0.75-fold higher) to that of the endogenous protein, whereas omental (2.1-fold) and subcutaneous (2.9-fold) adipose tissues exhibited higher levels ( Figure 1C) .
We previously demonstrated that loss-of-function mutations in Lmf1 result in diminished LPL activities. 12 To test if LPL is also affected by elevated Lmf1 expression, we determined lipase activities in tissues of aP2-Lmf1 mice. LPL activities were significantly higher in all transgenic adipose depots in both fasted ( Figure 2A ) and fed ( Figure I in the online-only Data Supplement) conditions. Furthermore, similar results were obtained in a second, independent line of aP2-Lmf1 mice ( Figure II in the online-only Data Supplement). These results suggest that endogenous Lmf1 levels limit the expression of LPL activity in adipose tissue.
Total tissue lipase activities measured in our experiments include both intracellular (ie, before secretion from adipocytes) and extracellular LPL, the latter representing functionally relevant enzyme. To determine if LPL activity is increased in the functional compartment of transgenic adipose tissue, fat pads were incubated with heparin ex vivo and lipase activity released into the medium was measured. Heparin-released LPL activity from transgenic adipose was 3-fold elevated compared to wild-type tissue ( Figure Next, we investigated potential molecular mechanisms responsible for increased LPL activity in transgenic tissues. Consistent with the posttranslational role of Lmf1 in LPL maturation, LPL mRNA expression was unchanged in tissues of aP2-Lmf1 mice ( Figure IVA in the online-only Data Supplement). However, the analysis of LPL protein expression by ELISA revealed distinct differences among adipose depots. In gonadal adipose, LPL mass was significantly increased in female aP2-Lmf1 mice and showed a trend toward that effect in males, which explains the higher LPL activities detected in this tissue ( Figure 2B ). In contrast, LPL mass was largely unaffected in omental and subcutaneous depots, with the exception of omental adipose in male mice ( Figure 2B ). These data suggest that in omental and subcutaneous adipose, a larger proportion of total LPL mass was present in a catalytically active form in aP2-Lmf1 mice. Indeed, calculation of LPL specific activity (ie, LPL activity per LPL mass) demonstrated that increased LPL activities were due to higher specific activity of the enzyme in these tissues ( Figure 2C ).
To assess the potential metabolic consequences of elevated adipose tissue LPL activity, we characterized metabolic parameters in aP2-Lmf1 mice. No changes were detected in body weight or composition, plasma parameters including lipid, glucose, and insulin levels or postheparin LPL activity (Table I in 
elevated LPL activity in Mck-Lmf1 transgenic Mice
The results obtained in aP2-Lmf1 mice prompted us to investigate whether the effects of Lmf1 overexpression on LPL extend to other major LPL-expressing tissues, such as heart and skeletal muscle. We used a 6.5-kb genomic DNA fragment encompassing the promoter, enhancer 1, exon 1, and intron 2 of the Mck gene to drive myc-Lmf1 expression in skeletal muscle and heart ( Figure 3A) . 27 As expected, myc-Lmf1 was specifically expressed in these tissues ( Figure 3B Consistent with a posttranslational mechanism, elevated LPL activities in Mck-Lmf1 tissues were not associated with increased LPL mRNA expression ( Figure IVB in the online-only Data Supplement). However, in contrast to aP2-Lmf1 adipose tissue, increased LPL activity was primarily due to higher LPL protein levels ( Figure 4B ). The only exception to this is female muscle tissue, which exhibited elevated LPL specific activity in transgenic animals ( Figure 4C ).
Similar to aP2-Lmf1 mice, postheparin LPL activity and metabolic parameters were indistinguishable between MckLmf1 and wild-type littermates with the exception of slightly lower HDL-cholesterol levels in transgenic males (Table II in the online-only Data Supplement).
LMF1 is associated With Postheparin LPL activities in Humans
Although tissue-specific overexpression of Lmf1 did not result in elevated plasma LPL activities in our transgenic mouse models, we hypothesized that genetic variation resulting in altered LMF1 expression in all tissues may affect postheparin plasma LPL activity in human subjects. To investigate whether common genetic variation influences LPL activity in human samples, we performed a tag-SNP approach in the LMF1 gene region (130kb). We genotyped 20 SNPs capturing 90% of the SNPs with minor allele frequency 10% in LMF1 in 1100 individuals from 92 Finnish dyslipidemic families. We did not attempt to capture geneticvariation with minor allele frequency 10%, as our study sample is not sufficiently powered to detect the effects of such variants. The SNPs were tested with continuous postheparin LPL activity levels in family-based association analyses using quantitative transmission disequilibrium test. 28, 29 In these extended families, the heritability estimate for LPL was 0.36 (SE50.08; P58310 27 ) indicating that LPL activity has a clear genetic component comparable to the heritability estimates of serum lipid levels. 30 We identified a common SNP (minor allele frequency50.4), rs3751666, in intron 1 of LMF1 to be associated with LPL activity (P53310 24 ) ( Figure 5 and Table III in the online-only Data Supplement). This result is gene-wide significant, as it surpasses the Bonferroni correction for 20 SNPs tested ( Bonferroni-adjusted P50.006). There was one other SNP (rs3829491) surpassing the Bonferroni correction ( Bonferroni-adjusted P50.038), however, this SNP does not represent an independent association signal as it is in high linkage disequilibrium with rs3751666 (r 2 50.96) (Table III in the online-only Data Supplement). The association of rs3751666 was only nominally significant with plasma TGs and HDL-cholesterol (P50.03 and 0.01, respectively).
Next, we used an imputation method to extend our association analysis to tagged and nontagged SNPs in the genomic region of LMF1 (57 additional SNPs). We imputed genotype dosage (expected allele counts 0-2) using the MACH program 31 and analysis of dosage data were performed with quantitative transmission disequilibrium test. Overall, we obtained the strongest evidence of association for the genotyped rs3751666 SNP even though we tested for association with many more common SNPs (minor allele frequency 5%) in the region ( Figure VII in the online-only Data Supplement). Furthermore, the strength of the association signal of the regional SNPs was highly correlated with the strength of their pairwise linkage disequilibrium with rs3751666 (r520.7 and P51310 212 ) ( Figure VII in the online-only Data Supplement) suggesting that rs3751666 is the only independent common association signal at this locus. The genotypic means (SEM) of LPL activity adjusted for age, sex, and kinship were 2251.07 μmol FA/h/mL for the A/A common homozygotes, 2171.06 μmol FA/h/mL for the A/G heterozygotes, and 2101.1 μmol FA/h/mL for the G/G rare homozygotes. In agreement with Lmf1 transgenic mouse data, these results suggest that variation in LMF1 expression and/ or activity may modulate LPL activity in humans. We did not observe significant associations between the 20 SNPs and postheparin hepatic lipase activity, consistent with this lipase being less dependent on LMF1 for maturation than LPL.
discussion
Previous characterization of loss-of-function mutations identified Lmf1 as a critical factor in the posttranslational maturation of lipases in mice and human subjects. 12, 15 The goal of the present study was to investigate whether altered Lmf1 expression also affects this process. We pursued 2 approaches to address this issue. First, we generated transgenic mouse lines overexpressing Lmf1 in various tissues. Characterization of these mice demonstrated that LPL activity was elevated in all transgenic tissues tested. Second, we sought genetic evidence for an effect of variable LMF1 expression on LPL in human subjects. Consistent with the mouse studies, we detected significant association between LMF1 SNPs and LPL activity in a dyslipidemic cohort. Taken together, our results extend the previously established role of Lmf1 as a required factor for lipase maturation and suggest that the expression level of this chaperone is a determinant of LPL activity.
Although LPL activity was uniformly increased in all Lmf1-transgenic tissues, initially distinct mechanisms seemed to be operating in different tissues. In some (gonadal adipose, heart, and muscle), elevated LPL mass was clearly responsible for increased LPL activity. In others (omental and subcutaneous adipose), higher specific activity of LPL without changes in LPL mass explained elevated tissue LPL activity. Despite the apparent differences, the direct effects of Lmf1 overexpression are likely to be the same in all tissues, namely enhanced LPL dimer assembly in the ER and increased rate of secretion of the active enzyme, as demonstrated in our study. However, the fate of extracellular LPL is tissue context-dependent and determined in large part by the expression of angiopoietin-like protein 4, which dissociates and inactivates the LPL dimer, 32 and the turnover rate of inactive LPL as a function of tissue perfusion and hepatic degradation. 33 Consistent with such tissue-specific differences, LPL specific activity was found to be highly variable between human adipose depots and adipose versus heart tissue in the mouse. 34, 35 In conclusion, LPL mass and specific activity in a given tissue are subject to the effects of intra-and extracellular biosynthetic and degradation pathways and the apparent variability in our transgenic models is a likely reflection of this complexity.
The aP2 promoter-driven transgenic construct resulted in variable expression in different adipose depots allowing us to assess the relationship between Lmf1 levels and LPL activity. Consistent with previous reports, subcutaneous and gonadal depots exhibited the highest and lowest level of Lmf1 transgene expression, respectively. 36 Accordingly, LPL activities showed a similar overall pattern across adipose depots and in general seemed to be commensurate with the degree of Lmf1 overexpression. An important caveat to the study on Mck-Lmf1 mice is that the transgene was expressed at supraphysiological levels, which limits the interpretation of this model. Nonetheless, in general agreement with the aP2-Lmf1 transgenics, LPL activity was elevated in the heart and muscle of Mck-Lmf1 mice, although several-fold overexpression of Lmf1 resulted in only 30% to 50% increases in LPL activity. It is conceivable that the relatively modest impact on LPL is due to a saturation effect. Alternatively, the differences between aP2-and Mck-Lmf1 transgenics may reflect distinct mechanisms involved in the regulation of LPL activity in adipose and muscle tissues. 37, 38 The metabolic effects of elevated tissue LPL activities remained undetectable in our transgenic mouse models. This is not unexpected and is consistent with previous studies on LPL-transgenic mice. For example, LPL overexpression in aP2-LPL mice, which exhibit similarly elevated LPL activities in adipose tissue as aP2-Lmf1 mice, had no effect on plasma lipids, postheparin LPL activity, or other metabolic traits. 39 Likewise, Mck-LPL transgenic mice with muscle-specific LPL overexpression exhibited wild-type levels of plasma lipids, glucose, and insulin.3 However, in contrast to tissue-specific models, transgenic mice overexpressing LPL in all tissues showed elevated plasma LPL activity and altered lipid traits. [40] [41] [42] Taken together, these results suggest that the metabolic effects of increased LPL activity limited to individual tissues may be too small to be detected or masked by compensatory changes. Potential compensatory mechanisms may involve reduced LPL expression in nontransgenic tissues or changes in the activities of posttranslational regulators of LPL, such as apolipoproteins C2, C3, and A5, and angiopoietin-like proteins 3 and 4. Our transgenic mouse studies suggested that Lmf1 expression level is a determinant of LPL activity. To extend this conclusion to humans, we tested the effects of LMF1 variation on LPL by performing association analyses between common genetic variants in the LMF1 region and postheparin plasma LPL activity in a dyslipidemic cohort. To the best of our knowledge, this is the first study to investigate the effects of common variants on LPL activity in human dyslipidemia. We detected gene-wide significant association between LPL activity and a tag-SNP (rs3751666) within the first intron of LMF1 suggesting that variation in LMF1 also influences LPL activity in humans. The association signal may be due to linkage disequilibrium with functional polymorphism(s) affecting the expression or function of LMF1. Alternatively, as rs3751666 occurs within a short distance (28 bp) from exon 2, it may directly affect splicing of the LMF1 message. Additional larger cohorts characterized for the lipase phenotype will be required to replicate the association with rs3751666 and fine-map the functional variant.
The apparent lack of associations between LMF1 and plasma lipid levels in our study and a previous genome-wide association study5 is likely due to insufficient power to detect small effects. Consistent with the generally small effects of common variants, the impact of rs3751666 on LPL activity is relatively modest. Furthermore, LPL is only one of many factors in the determination of plasma lipid levels. Indeed, LPL is responsible for only 8.8% and 5.6% of the variation in plasma TG and HDL-C levels, respectively, in our cohort. In summary, we provided genetic evidence indicating that common variants of LMF1 affect plasma LPL activity in humans, which is consistent with the quantitative effects of Lmf1 expression on tissue LPL in mouse models. Although association with lipids could not be detected in the present study, the role of LMF1 in plasma lipid metabolism has been previously established. In particular, rare LMF1 variants, which were not interrogated in the current analysis or other genome-wide association studies, have been demonstrated to exert major effects on plasma TG levels. 12, 15, 43 The main conclusion of the present study is that variation in Lmf1 expression is associated with changes in LPL activities. Nonetheless, important questions remain to be addressed in future studies. For example, the molecular mechanisms responsible for increased LPL specific activity in some transgenic tissues, but elevated LPL mass in others is not well understood. It is also unclear whether hepatic lipase and endothelial lipase are similarly affected by Lmf1 overexpression. Finally, our results raise the interesting possibility of lipase regulation through the modulation of Lmf1 expression and/or activity. Further studies are warranted to investigate the physiological contexts and molecular mechanisms affecting Lmf1 expression and function.
acknowledgments
We thank the Finnish individuals who participated in this study. We also thank Lawrence Castellani, Sarada Charugundla, Jessica Latter and Cindy Montes for laboratory technical assistance.
sources of Funding
This work was supported by the National Institutes of Health grants HL095056 (to P.P.), HL028481 (to P.P. and M.P.), and the Cedars-Sinai Medical Center. 
